BioScrip (BIOS) Misses Q3 EPS by 7c

BioScrip (NASDAQ: BIOS) reported Q3 EPS of ($0.12), $0.07 worse than the analyst estimate of ($0.05). Revenue for the quarter came in at $224.5 million versus the consensus estimate of $223.26 million.

The Company reconfirms its plan to achieve between $14 million to $17 million in Home Solutions cost synergies over the next 12 to 18 months. Additionally, the Company is in the process of finalizing its evaluation of an incrementally larger amount of additional synergies over and above the $14 million to $17 million of synergies initially identified which we also believe may be achievable as incremental additional cost savings over the next 12 to 18 months.

For earnings history and earnings-related data on BioScrip (BIOS) click here.

You May Also Be Interested In

• Arxis, Inc. (ARXS) Reports Q2 EPS of $0.28; offers guidance
• Sanofi (SNY) Tops Q2 EPS by 100c
• Yum China (YUMC) Tops Q2 EPS by 3c